Integrated Medical Professionals, PLLC, the Largest U.S.-based Urology Group Practice, Selects PatientPoint
ORLANDO, Fla.–(BUSINESS WIRE)– PatientPoint™, a provider of self-service and revenue cycle management applications, today announced a partnership with Integrated Medical Professionals PLLC, (IMP), the largest urology group in the United States. The 40 location, New York metropolitan area based group will leverage PatientPoint’s self-service check-in technology to supplement existing processes for improving patient data collection and associated reporting.
“By collecting self-reported patient data gathered during an automated check-in process, we expect to gather more in-depth information, while streamlining workflow for our staff,” said W. Price Dunaway, COO of IMP. “Real-time data collection and detailed patient health surveys will enable our providers to better address additional preventative care issues, further enhancing patient care.”
As patients arrive for an appointment at an IMP office, they check-in at a self-service kiosk or tablet, which prompts them to enter demographic and insurance information. Co-pays and any outstanding balances may also be collected at that time. Patients then receive material addressing their specific health risks, preventative screening details and health-related surveys, which are filled out directly on the screen.
Real-time technology allows for the patient’s information to be directly integrated into the group’s electronic health record and other systems. Following, the physician can review and assess the data before the patient encounter, enabling more meaningful patient-provider interaction. For example, an older male patient may be reminded that he is overdue for his prostate cancer screening, which can then be addressed the during the exam.
For providers and payers, this approach enables both parties to obtain the patient assessment earlier, resulting in better tracking of patient-specific details that are imperative for quality reporting requirements and pay-for-performance measures. This real-time interaction also provides an opportunity for patients to receive targeted health information and educational materials.
“As a pioneer in technology, IMP’s decision to utilize self-service applications continues to position them as a thought leader in their field. The group’s approach will not only empower its patients to take charge of managing their health, but also help its more than 100 physicians and a number of payers receive valuable patient information quickly and easily,” said Raj Toleti, CEO of PatientPoint. “Implementing a process that benefits providers, payers and patients ultimately leads to savings for all and is imperative as the healthcare industry strives to improve the quality of care.”
About Integrated Medical Professionals, PLLC
Integrated Medical Professionals, PLLC, provides diagnostic and therapeutic services to patients in the greater New York Metropolitan area. With over 100 physicians, IMP is the largest urology group in the country serving patients the highest level of care through integration of surgical specialists at the point of patient contact. For more information, visit.
About PatientPoint™
PatientPoint™ provides self-service solutions and end-to-end billing services that enable physician practices to streamline administrative and clinical workflow, expedite revenue collection, conduct real-time claims adjudication and improve financial performance, including online pre-registration, patient check-in, scheduling, bill payment and mobile charge capture applications. The company also offers health IT consulting services to individual practices and regional extension centers. For more information, visit www.patientpointkiosk.com.
This entry was posted in Press. Bookmark the permalink
Dr. Savvas Mendrinos wins 2nd prize at Society of Uroradiology.
Dr. Savvas Mendrinos, pathologist at Integrated Medical Professionals, was awarded the second place prize for his abstract on the histologic features of prostate cancer and detectability at the annual meeting of the Society of Uroradiology. The study was conducted in collaboration with the department of Radiology and Urology of NYU’s School of Medicine, while Dr. Mendrinos was faculty in their Pathology Department.
The Society of Uroradiology is organized to promote interest and investigation in the advancement of urinary and genital tract imaging, and to stimulate the study of both normal and abnormal processes. The organization’s emphasis is the integration of current imaging and interventional practice. Membership is offered to physicians and other scientists who have an interest in the practice, teaching, or research of genitourinary imaging. The conference was held March 20 – 25, 2011 at the Park Hyatt Aviara Resort in Carlsbad, California.
Dr. Mendrinos’ abstract looked at how predictable the aggressiveness of prostate cancer is via biopsy, MRI and subsequent prostatectomy (surgical removal of all or part of the prostate gland). Patients who had a positive biopsy result were given an MRI, followed by a prostatectomy. Dr. Mendrinos mapped out the entire prostatectomy specimens and cataloged the Gleason score (rating system which tells how closely a prostate tumor resembles normal prostate tissue; the lower the number, the lower grade the cancer). Dr. Mendrinos’ findings were compared to the patient’s pre-prostatectomy MRI and biopsy. He found that visible tumors were those larger than 6mm with a persistent growth of dense fibrous tissue around the tumor, and a Gleason score of 7 and higher. Tumors with a Gleason score of 6 were not visible by MRI, unless they were larger than 6mm with aggressive activity in the fibrous tissue surrounding it.
This study’s significance is that the aggressive and clinically important tumors can be detected by doing a post or even a pre-biopsy MRI in clinically high risk patients. If the post biopsy MRI is negative, it is likely the disease in the prostate is low grade. This critical information can be instrumental in developing the standard of care protocols for watchful waiting vs. active treatment.